8-K: NeueHealth Reports Strongest Financial Performance to Date in 2024, Driven by Value-Based Care Model

NeueHealth announces its Q4 and full-year 2024 financial results, highlighting its strongest financial performance to date and significant growth in consumers served.

Summary

• NeueHealth reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company achieved its strongest financial performance to date in 2024, driven by its value-driven, consumer-centric care model.
• NeueHealth reported positive Adjusted EBITDA for the fourth consecutive quarter in 2024.
• The company served 717,000 consumers to start 2025, a 48% increase compared to 2024.
• Revenue for 2024 was $936.657 million, compared to $1,160.802 million in 2023.
• Net loss for 2024 was $(99.717) million, compared to $(1,265.808) million in 2023.
• Adjusted EBITDA for 2024 was $22.496 million, compared to $(8.480) million in 2023.
• The company is set to be acquired by NH Holdings 2025, Inc., indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. (NEA).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's improved financial performance and growth in consumers served, but tempered by the net loss and pending acquisition.

Positives

• The company delivered its strongest financial performance to date in 2024.
• NeueHealth achieved positive Adjusted EBITDA for the fourth consecutive quarter in 2024.
• The company experienced significant growth in consumers served, reaching 717,000 to start 2025.
• Net loss improved significantly to $(99.717) million for 2024, compared to $(1,265.808) million in 2023.

Negatives

• The company reported a net loss of $(99.717) million for the year ended December 31, 2024.
• Revenue decreased from $1,160.802 million in 2023 to $936.657 million in 2024.

Risks

• The failure to complete the transaction with NH Holdings 2025, Inc. on the anticipated terms and timeframe.
• Potential litigation relating to the transaction.
• Adverse reactions or changes to business relationships resulting from the announcement of the transaction.
• The risk that the company's stock price may decline significantly if the transaction is not consummated.
• Restrictions during the pendency of the transaction that may impact the company's ability to pursue certain business opportunities.
• The company's ability to continue as a going concern.
• The company's ability to comply with the terms of its credit facilities.
• The company's ability to receive the remaining proceeds from the sale of its Medicare Advantage business in California in a timely manner.
• The company's ability to obtain any short or long term debt or equity financing needed to operate its business.
• Potential disruptions to the business due to the transaction or corporate restructuring and any resulting headcount reduction.

Future Outlook

The company is focused on serving more consumers in new and existing markets and building on relationships with payors and providers across the industry in 2025 and beyond.

Management Comments

• In 2024, we delivered our strongest financial performance to date, demonstrating the power of our value-driven, consumer-centric care model, said Mike Mikan, President and CEO of NeueHealth.
• I am excited for the future of our company and believe we are well-positioned to continue to bring a seamless, more coordinated care experience to all in 2025 and beyond.

Industry Context

NeueHealth's focus on value-driven, consumer-centric care aligns with the broader industry trend towards value-based healthcare models that aim to improve quality and reduce costs.

Comparison to Industry Standards

• It is difficult to compare NeueHealth directly to industry standards without more specific information on its market segments and business model.
• However, companies like Oak Street Health and One Medical also focus on value-based care and consumer-centric models.
• Their financial performance and growth metrics could provide a benchmark for comparison.

Stakeholder Impact

• Shareholders are urged to read the proxy statement and other relevant documents before making any voting or investment decision.
• The transaction may impact employees due to potential corporate restructuring and headcount reduction.
• The company aims to provide high-quality, coordinated care to health consumers.
• The company seeks to build relationships with payors and providers across the industry.

Next Steps

• The company will discuss the results, strategy, and outlook on a conference call with investors.
• The company will send or provide the definitive version of the Proxy Statement to Company stockholders.
• The Company, affiliates of the Company and affiliates of NEA intend to jointly file a transaction statement on Schedule 13E-3 (the Schedule 13E-3 ) with the SEC.

Key Dates

Keywords

NeueHealth, financial results, Adjusted EBITDA, value-based care, healthcare, merger, acquisition, revenue, net loss, consumers